{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T09:01:52Z","timestamp":1780995712311,"version":"3.54.1"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000864","name":"The Michael J Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bioorg.2026.109994","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T23:57:19Z","timestamp":1778889439000},"page":"109994","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Constrained peptide mimics of the LRRK2 C-terminal Helix inhibits its kinase activity"],"prefix":"10.1016","volume":"179","author":[{"given":"Tiancheng","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista K.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana A.","family":"Martinez Fiesco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahaira","family":"Naaldijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Fasiczka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Besma","family":"Brahmia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid Alvarez","family":"de la Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"LeClair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma G.","family":"Steude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Hilfiker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen J.","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.109994_bb0005","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-080952","article-title":"Projections for prevalence of Parkinson\u2019s disease and its driving factors in 195 countries and territories to 2050: modelling study of global burden of disease study 2021","volume":"388","author":"Su","year":"2025","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.bioorg.2026.109994_bb0010","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.molmed.2024.07.003","article-title":"LRRK2 in Parkinson's disease: upstream regulation and therapeutic targeting","volume":"30","author":"Xiong","year":"2024","journal-title":"Trends Mol. Med."},{"issue":"5","key":"10.1016\/j.bioorg.2026.109994_bb0015","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1056\/NEJMra2401857","article-title":"Parkinson\u2019s disease","volume":"391","author":"Tanner","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.bioorg.2026.109994_bb0020","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41582-019-0301-2","article-title":"LRRK2 in Parkinson disease: challenges of clinical trials","volume":"16","author":"Tolosa","year":"2020","journal-title":"Nat. Rev. Neurol."},{"issue":"19","key":"10.1016\/j.bioorg.2026.109994_bb0025","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1042\/BCJ20210375","article-title":"Impact of type II LRRK2 inhibitors on signaling and mitophagy","volume":"478","author":"Tasegian","year":"2021","journal-title":"Biochem. J."},{"issue":"11","key":"10.1016\/j.bioorg.2026.109994_bb0030","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1021\/acschembio.1c00487","article-title":"Allosteric inhibition of Parkinson\u2019s-linked LRRK2 by constrained peptides","volume":"16","author":"Helton","year":"2021","journal-title":"ACS Chem. Biol."},{"issue":"3","key":"10.1016\/j.bioorg.2026.109994_bb0035","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1124\/jpet.115.227587","article-title":"MLi-2, a potent, selective, and centrally active compound for exploring the therapeutic potential and safety of LRRK2 kinase inhibition","volume":"355","author":"Fell","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109994_bb0040","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41531-023-00544-7","article-title":"Perspective on the current state of the LRRK2 field","volume":"9","author":"Taymans","year":"2023","journal-title":"NPJ Parkinsons Dis"},{"issue":"11","key":"10.1016\/j.bioorg.2026.109994_bb0045","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1021\/acschemneuro.3c00259","article-title":"Doubly constrained C-terminal of roc (COR) domain-derived peptides inhibit leucine-rich repeat kinase 2 (LRRK2) dimerization","volume":"14","author":"Pathak","year":"2023","journal-title":"ACS Chem. Nerosci."},{"issue":"7837","key":"10.1016\/j.bioorg.2026.109994_bb0050","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/s41586-020-2673-2","article-title":"Structure of LRRK2 in Parkinson\u2019s disease and model for microtubule interaction","volume":"588","author":"Deniston","year":"2020","journal-title":"Nature"},{"issue":"13","key":"10.1016\/j.bioorg.2026.109994_bb0055","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.1016\/j.cell.2021.05.004","article-title":"Structural analysis of the full-length human LRRK2","volume":"184","author":"Myasnikov","year":"2021","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.bioorg.2026.109994_bb0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3001427","article-title":"LRRK2 dynamics analysis identifies allosteric control of the crosstalk between its catalytic domains","volume":"20","author":"Weng","year":"2022","journal-title":"PLoS Biol."},{"issue":"4","key":"10.1016\/j.bioorg.2026.109994_bb0065","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1042\/BCJ20230477","article-title":"Role of the leucine-rich repeat protein kinase 2 C-terminal tail in domain cross-talk","volume":"481","author":"Sharma","year":"2024","journal-title":"Biochem. J."},{"key":"10.1016\/j.bioorg.2026.109994_bb0070","first-page":"98","article-title":"NetWheels: a web application to create high quality peptide helical wheel and net projections","volume":"7","author":"Mol","year":"2024","journal-title":"Journal of Bioinformatics and Systems Biology"},{"issue":"24","key":"10.1016\/j.bioorg.2026.109994_bb0075","doi-asserted-by":"crossref","first-page":"5891","DOI":"10.1021\/ja000563a","article-title":"An all-hydrocarbon cross-linking system for enhancing the helicity and metabolic stability of peptides","volume":"122","author":"Schafmeister","year":"2000","journal-title":"J. Am. Chem. Soc."},{"issue":"2","key":"10.1016\/j.bioorg.2026.109994_bb0080","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/med.21540","article-title":"Recent structural advances in constrained helical peptides","volume":"39","author":"Skowron","year":"2019","journal-title":"Med. Res. Rev."},{"issue":"17","key":"10.1016\/j.bioorg.2026.109994_bb0085","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1042\/BCJ20220161","article-title":"Impact of 100 LRRK2 variants linked to Parkinson\u2019s disease on kinase activity and microtubule binding","volume":"479","author":"Kalogeropulou","year":"2022","journal-title":"Biochem. J."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109994_bb0090","doi-asserted-by":"crossref","DOI":"10.1038\/s41531-023-00624-8","article-title":"A potential patient stratification biomarker for Parkinson s disease based on LRRK2 kinase-mediated centrosomal alterations in peripheral blood-derived cells","volume":"10","author":"Naaldijk","year":"2024","journal-title":"Npj. Parkinsons Dis."},{"key":"10.1016\/j.bioorg.2026.109994_bb0095","first-page":"11","article-title":"The LRRK2 signaling network converges on a centriolar phospho-Rab10\/RILPL1 complex to cause deficits in centrosome cohesion and cell polarization","author":"Lara Ordonez","year":"2022","journal-title":"Biol. Open"},{"issue":"1","key":"10.1016\/j.bioorg.2026.109994_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2022.102024","article-title":"Protocol to measure centrosome cohesion deficits mediated by pathogenic LRRK2 in cultured cells using confocal microscopy","volume":"4","author":"Fdez","year":"2023","journal-title":"STAR Protoc."},{"key":"10.1016\/j.bioorg.2026.109994_bb0105","first-page":"7","article-title":"A pathway for Parkinson\u2019s disease LRRK2 kinase to block primary cilia and sonic hedgehog signaling in the brain","author":"Dhekne","year":"2018","journal-title":"Elife"},{"issue":"32","key":"10.1016\/j.bioorg.2026.109994_bb0110","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2402206121","article-title":"Loss of primary cilia and dopaminergic neuroprotection in pathogenic LRRK2-driven and idiopathic Parkinson\u2019s disease","volume":"121","author":"Khan","year":"2024","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.bioorg.2026.109994_bb0115","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s10616-023-00591-1","article-title":"Deciphering variations in the endocytic uptake of a cell-penetrating peptide: the crucial role of cell culture protocols","volume":"75","author":"Diaz","year":"2023","journal-title":"Cytotechnology"},{"issue":"23","key":"10.1016\/j.bioorg.2026.109994_bb0120","doi-asserted-by":"crossref","first-page":"7119","DOI":"10.1038\/s44318-025-00608-9","article-title":"TXNIP mediates LAT1\/SLC7A5 endocytosis to limit amino acid uptake in cells entering quiescence","volume":"44","author":"Kahlhofer","year":"2025","journal-title":"EMBO J."},{"issue":"3","key":"10.1016\/j.bioorg.2026.109994_bb0125","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1021\/bc700289w","article-title":"Cellular internalization and distribution of arginine-rich peptides as a function of extracellular peptide concentration, serum, and plasma membrane associated proteoglycans","volume":"19","author":"Kosuge","year":"2008","journal-title":"Bioconjug. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109994_bb0130","doi-asserted-by":"crossref","DOI":"10.1002\/pep2.24251","article-title":"Leucine rich repeat kinase 2 (LRRK2) peptide modulators: recent advances and future directions","volume":"114","author":"Helton","year":"2022","journal-title":"Pept. Sci."},{"issue":"6","key":"10.1016\/j.bioorg.2026.109994_bb0135","doi-asserted-by":"crossref","DOI":"10.1002\/pep2.24374","article-title":"Disruption of the LRRK2-FADD interface using constrained peptides","volume":"116","author":"Alexander","year":"2024","journal-title":"Pept. Sci."},{"issue":"5","key":"10.1016\/j.bioorg.2026.109994_bb0140","doi-asserted-by":"crossref","DOI":"10.1002\/psc.3563","article-title":"Targeting Rab-RILPL interactions as a strategy to downregulate pathogenic LRRK2 in Parkinson\u2019s disease","volume":"30","author":"Alexander","year":"2024","journal-title":"J. Pept. Sci."},{"issue":"7","key":"10.1016\/j.bioorg.2026.109994_bb0145","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15071999","article-title":"Cell-penetrating and targeted peptides delivery systems as potential pharmaceutical carriers for enhanced delivery across the blood-brain barrier (BBB)","volume":"15","author":"Ghorai","year":"2023","journal-title":"Pharmaceutics"},{"issue":"5","key":"10.1016\/j.bioorg.2026.109994_bb0150","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.1898","article-title":"Targeting the central nervous system: from synthetic nanoparticles to extracellular vesicles-focus on Alzheimer\u2019s and Parkinson\u2019s disease","volume":"15","author":"Hernando","year":"2023","journal-title":"WIREs Nanomed. Nanobiotechnol."},{"issue":"2","key":"10.1016\/j.bioorg.2026.109994_bb0155","doi-asserted-by":"crossref","DOI":"10.1002\/jex2.70116","article-title":"Extracellular vesicle-mediated delivery of constrained peptides disrupts the pathogenic interaction of LRRK2-FADD in Parkinson\u2019s disease","volume":"5","author":"Zheng","year":"2026","journal-title":"J. Extracell. Biol."},{"key":"10.1016\/j.bioorg.2026.109994_bb0160","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2020.00443","article-title":"LRRK2 at the interface between peripheral and central immune function in Parkinson\u2019s","volume":"14","author":"Wallings","year":"2020","journal-title":"Front. Neurosci."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109994_bb0165","doi-asserted-by":"crossref","DOI":"10.1038\/s41531-021-00170-1","article-title":"Is LRRK2 the missing link between inflammatory bowel disease and Parkinson\u2019s disease?","volume":"7","author":"Herrick","year":"2021","journal-title":"Npj. Parkinsons Dis."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826005304?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826005304?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T08:17:50Z","timestamp":1780993070000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826005304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":33,"alternative-id":["S0045206826005304"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109994","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Constrained peptide mimics of the LRRK2 C-terminal Helix inhibits its kinase activity","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109994","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109994"}}